The distribution of Sonic Hedgehog (Shh) is a highly regulated and critical process for development. Several negative feedback mechanisms are in place, including the Shh-induced upregulation of Hedgehog interacting protein (Hhip). Hhip sequesters Shh, leading to a non-cell autonomous inhibition of the pathway. Hhip over-expression has a severe effect on neural tube development, raising the question why normal sites of Hhip expression have a seemingly unimpaired response to Shh. Here we show that while Hhip is able to leave its sites of synthesis to inhibit Shh non-cell autonomously, activation of Smoothened (Smo) drastically increases Hhip internalization and degradation cell autonomously. Although Hhip is unable to cell autonomously inhibit the consequences of Smo activation, it can inhibit the Shh response non-cell autonomously. Our data provide a mechanism by which the Shh ligand can activate the response and negate cell autonomous effects of Hhip, while Hhip can still induce non-cell autonomous inhibition.
Introduction
Signal transduction by members of the Hedgehog (Hh) family of molecules is essential during development. As morphogens, Hh proteins are secreted from localized sources to induce distinct concentration dependent cellular responses. Highly regulated feedback mechanisms are in place to ensure that Hh gradients are established appropriately within responding tissues. Of all the Hedgehog (Hh) ligands, Shh has been most intensely studied, Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms for instance in neural tube patterning. Shh is synthesized in the notochord and in the floor plate of the developing neural tube, providing sources of a ventral to dorsal gradient. This Shh gradient induces a spatially and temporally dependent expression of transcription factors that determine specific neural cell fates. The Shh response is initiated by two membrane proteins, Patched1 (Ptch1) and Smoothened (Smo). Ptch1 is the receptor for Hh, while Smo is the activator of the downstream pathway. In the absence of Hh ligands, Ptch1 suppresses the activity of Smo, which is released upon Hh binding to Ptch1, allowing Smo to activate its downstream targets 1 .
Shh gradient formation is regulated by several cell surface proteins that bind to and limit the distribution of Shh. One of these proteins is Hhip, a vertebrate specific protein that binds Shh 2 . Like Ptch1, Hhip is transcriptionally upregulated in response to Shh signaling and consequently Hhip is highly expressed just dorsal to the floor plate. Hhip overexpression in animals causes severe skeletal and pituitary defects 2, 3 while Hhip loss of function causes an increase in Hh signaling resulting in lung, skeleton, gut, and pancreas malformations 4, 5 . Interestingly, the consequences of Hhip loss of function are relatively minor in the spinal cord, although the function of Hhip in the developing spinal cord becomes apparent when Ptch1 activity is reduced 6, 7 . From these studies, the general idea has emerged that Hhip acts at the cell surface of the cell that expresses it to bind and sequester Shh, making it unavailable to Ptch1 for pathway activation both cell autonomously and to nearby cells. This sequestration model is consistent with the proposed role of Hhip function as a barrier that decreases the amount of Shh available to cells distal to the Shh source and Hhip expression domain, resulting in inhibition of Shh activity non-cell autonomously. In the brain, soluble forms of Hhip have been detected 8 , raising questions regarding the nature of the non-cell autonomous inhibition by Hhip.
Here we investigated the distinct cell autonomous and non cell autonomous roles of Hhip in the inhibition of the Shh response. Consistent with other reports 6, 9 , we show that Hhip expression by itself had a severe effect on neural tube development, raising the question of why the Shh-induced expression of Hhip does not result in a cell-autonomous inhibition of the Shh response. We identify a mechanism by which activation of Smo results in a rapid internalization and degradation of Hhip, thus mitigating the consequences of Hhip expression cell autonomously, but allowing Hhip to inhibit the Shh response at a distance.
Results

Shh binding domain of Hhip is necessary for Shh inhibition
Hhip is a multidomain protein. To assess the functions of these domains we created the following deletions of: the Shh binding domain, HhipΔL2 10 ; the two EGF domains, HhipΔEGF; and a stretch of 20 amino acids that contains 9 arginines that we called the arginine rich region (AR), HhipΔAR (Fig. 1a) . The AR is located within the cysteine rich domain (CRD) of Hhip, which shares characteristics with Frizzled-like CRDs 10, 11 . The mutants were assessed for their ability to inhibit the Shh response in the developing chick neural tube. At high concentrations Shh induces motor neuron precursors, which upon becoming postmitotic, express the marker Hb9 12 . Even at low concentrations, Shh represses Pax7 expression, limiting Pax7 to the dorsal half of the neural tube 13 . We examined the expression of these markers as a measure of Shh activity in the neural tube.
Ectopic expression of Hhip in the ventral neural tube resulted in Hb9 inhibition (Fig. 1b) and an expansion of the Pax7 domain (Fig. 1c) , demonstrating an inhibition of the Shh response. The expansion of Pax7 included expression in cells that did not express Hhip, indicating that Hhip inhibited the Shh response in neighbouring cells. These findings are in agreement with previous observations that demonstrate a non-cell autonomous action of Hhip on Shh in the neural tube 6, 9 . Expression of HhipΔL2 did not inhibit Shh activity since both Hb9 and Pax7 expression were not affected (Fig. 1d, e) , confirming that the Shh binding function of Hhip is necessary to inhibit the Shh response in the neural tube and is in line with previous experiments in zebrafish and cell culture 10, 14 . Moreover, HhipΔAR and HhipΔEGF inhibited the Shh response similar to wild type Hhip (Fig. 1f-i) , indicating that these domains are dispensable for Hhip inhibition of Shh. HhipΔEGF-mediated Hb9 inhibition and Pax7 expansion included domains ventral to the HhipΔEGF expressing cells (Fig. 1h, i) . Currently, Hhip is thought to act at the cell surface of the cell that expresses it (cell autonomously), binding and sequestering Shh, making it unavailable to Ptch1 for pathway activation in neighboring cells. This model implies that the main effects of Hhip are a barrier or a sieve that slows down Shh transport, resulting in inhibition of Shh activity cell nonautonomously. If Hhip indeed acts as a barrier, then Hhip expression must be between the Shh source and the domain where the Shh response is inhibited. Our results are inconsistent with such a barrier function of Hhip, and a possible explanation for this is the existence of a form of Hhip that is released from cells and moves into the Shh gradient to inhibit the Shh response at a distance.
Hhip released from cells interacts with and inhibits Shh
In electroporated neural tubes, the side of the neural tube expressing Hhip was often smaller than the opposite side (Fig 1j-q) , consistent with an important function of Shh as a mitogen and the interference by Hhip with this role 15 . To determine whether Hhip is released from cells that synthesize it, or if the observation in vivo was due to the effect of a deformed/ shortened neural tube, we assessed the localization of Hhip in cultured cells. MDCK cells transfected with Hhip, or an untethered form of Hhip lacking the C-terminal membrane anchor, HhipΔC22, in combination with GFP, were co-cultured with (independently) Shh transfected cells. Both Hhip and HhipΔC22 were detected on Shh expressing cells, but not on other cells (Fig. 2d, f) , likely due to a direct interaction between Hhip and Shh. These observations support the idea that Hhip is released from cells that synthesize it, indicating that at least some of the non-cell autonomous Shh inhibition is due to Hhip release.
Previous studies have mapped the Hhip and Shh binding regions important for interaction and have also noted that lipid modification of Shh is not a requirement 2, 10, 11 . However, we wanted to assess the interaction between Shh and the Hhip protein that is released from cells. Cells expressing either Hhip or Shh were co-cultured, and Hhip and Shh were coimmunoprecipitated from cell lysates and culture medium. Hhip bound Shh in both cell lysates and medium (Fig. 2g) . In contrast, the untethered mutant, HhipΔC22, showed robust binding in culture medium but very little in cell lysates, indicating that most was released from cells. Both HhipΔEGF and HhipΔAR were able to bind Shh in both lysates (data not shown) and culture medium (Fig. 2h) , indicating that the AR and EGF domains do not play a role in the release from cells or binding to Shh. HhipΔL2, did not bind Shh (Fig. 2i) . These data indicate that wild type Hhip, despite having a C-terminal helix inserted into the membrane, is released from cells and able to bind to Shh via Hhip L2 domain.
To assess whether released Hhip can inhibit signaling by endogenously expressed Shh, we performed reporter assays in Shh-LIGHT II cells 16 cultured in aggregates with MIA PaCa-2 cells, which express high amounts of Shh ligand 17 . MIA PaCa-2-induced Gli-luciferase activity was Shh ligand-mediated; addition of the Shh blocking antibody 5E1 decreased pathway activity (Fig. 2j) . Hhip, HhipΔC22, and HhipΔAR conditioned medium all significantly reduced Gli-luciferase activity, further supporting the efficacy of a non-cell autonomous action of Hhip.
Shh and Smo induces Hhip degradation cell autonomously
Hhip was detectable when co-cultured with cells independently transfected with Shh ( Fig.  2d ), but we were unable to detect Hhip in cells that also expressed Shh. Although Hhip and Shh are not known to be expressed in the same cells in vivo, we nevertheless decided to examine why Shh expression in the same cells prevented the detection of Hhip. HEK 293T cells were cotransfected with Hhip and Shh or the inactive C-terminal processed form of Shh, ShhC (Fig 3a, lane 1-2) . Hhip was present at much lower levels in cells expressing Shh than in cells expressing ShhC. This effect was not a consequence of vector backbone differences (Fig 3b, lanes 19-21) , and Shh was not affected by Hhip cotransfection (Fig 3b,  lanes 3 and 6) . To further test whether Shh/Hhip binding is important for the loss of Hhip, we co-transfected HhipΔL2 with Shh or ShhC (lanes 11 and 12) and found that Shh also caused a loss of HhipΔL2. These results indicate that Hhip stability is independent of Hhip binding to Shh and instead implicates Shh pathway activation in the degradation of Hhip.
To test whether Hhip degradation is mediated by the activation of the pathway, we cotransfected Hhip with wild type Smo, or an activated form of Smo, SMOM2 18 . Both Smo and SMOM2 decreased the amount Hhip and HhipΔL2 detected in cell lysates (Fig. 3a , lanes 3, 5, 13, 15). HhipΔAR, however, was resistant to degradation when co-expressed with Shh, Smo, and SMOM2 (Fig. 3a , lanes 6-10), yet it is an efficient inhibitor of the response in vivo. The EGF domain had no effect on Hhip stability (Fig 3b) (Fig. 3a lane 1-5 ). This is consistent with the lower activity of SmoΔCRD compared to Smo 19 . HhipΔAR protein was not affected by cotransfection of SmoΔCRD (lane 9). Co-transfection with Ptch1 did not affect Hhip protein in cell lysates (Fig. 3c, lane 1) . Altogether, these results indicate that the instability of Hhip is mediated via its AR domain at the level of or downstream of Smo activation. To further determine whether the activity of the Shh pathway downstream of Smo affects Hhip protein levels, we cotransfected Hhip with the repressor form of Gli3, Gli3R 20 (Fig 3d) .
Overexpression of Gli3R did not increase the stability of Hhip, indicating that transcriptional activation of Shh pathway is not involved in the instability of Hhip.
Shh induces Smo trafficking to the cell surface and the primary cilium, while the Shh/Ptch1 complex traffics to late endosomes [21] [22] [23] . Since both Shh and Smo dramatically reduce Hhip levels in cells, we assessed if Shh activation results in Hhip internalization and trafficking towards late endosomes and lysosomes for degradation, analogous to Ptch1. Both chloroquine and folimycin A prevent endosome acidification and thus late endosome maturation. Both drugs increased the levels of Hhip and Ptch1 (Fig. 3d lanes 1-4) , indicating that, like Ptch1, the degradation of Hhip occurs in lysosomes. This idea was further supported by the finding that treatment with MG132, a proteasome inhibitor, did not affect Hhip. When Hhip and Shh were coexpressed and treated with these inhibitors, there was a partial rescue of Hhip protein by chloroquine and folimycin A treatment from the Shhmediated degradation (lanes 5-9). Taken together, these data indicate that both Shh and Smo can induce a rapid internalization of Hhip to degrade it.
To further demonstrate that Shh pathway activation increases the turnover of Hhip, we examined Hhip expression in Ptch1−/− MEFs. In these cells, pathway activity is high due to the absence of Ptch1-mediated inhibition of Smo. Hhip could not be detected in these cells when cotransfected with vector or ShhC (Fig. 3e) . In contrast, restoring Smo regulation by the co-expression of Ptch1 increased Hhip levels such that it was detectable in this steady state situation. Chloroquine treatment rescued Hhip in control, ShhC, and Ptch1 cotransfected cells, although we could not rescue the effect of Shh on Hhip stability. These data demonstrate that an activated Shh pathway causes lysosomal Hhip degradation.
In response to Shh, Hhip has been shown to colocalize with Smo, mediating the internalization of both components 14 . We tested if stabilization of Hhip protein by mutation or drugs, would allow the detection of an interaction between Hhip and Smo. Only upon treatment with chloroquine did Hhip and Smo co-immunoprecipitate, whereas Hhip and SmoΔCRD co-immunoprecipitated regardless of drug treatment (Fig. 3f lanes 1-5) . HhipΔAR and Smo co-immunoprecipitated with or without chloroquine, yet we detected weak interaction between HhipΔAR and SmoΔCRD (lanes 6-10). These results indicate that both the Hhip AR and the CRD of Smo are not required for interaction, and that the observed interaction was most likely due to the lower activity of SmoΔCRD and the higher stability of HhipΔAR.
Activity of Hhip despite cell autonomous Smo activation
To determine if Hhip can still function as an inhibitor of Shh activity when expressed with a Shh activator, we co-electroporated Hhip mutants with SMOM2 or SmoΔCRD in the neural tube. Hb9 was repressed and there was ventral expansion of Pax7 in cells adjacent to those electroporated with Hhip, HhipΔC22, or HhipΔAR and SMOM2 and Hhip and SmoΔCRD (Fig 4a-h ). This demonstrates that Hhip non-cell autonomously inhibited the Shh response in nearby cells. SMOM2 and SmoΔCRD effects were strictly cell autonomous because Hb9 expression and Pax7 repression was only observed in Smo electroporated cells. These results also indicate that Hhip did not antagonize effects of SMOM2 and SmoΔCRD, consistent with the idea that Hhip acts upstream of Smo. But how do these data reconcile with the biochemistry, where SMOM2 expression leads to Hhip degradation? One explanation might be the higher expression levels obtained with electroporation resulting in sufficient release of Hhip to inhibit the Shh response non-cell autonomously. Alternatively, Hhip might be able to bind Shh that is present in the neural tube before being degraded.
Since Hhip inhibited Hb9 in the ventral neural tube even when Hhip electroporated cells were located dorsal to the Hb9 domain and distal to the Shh source (Fig. 4a) , we examined the consequences of expressing untethered Hhip (HhipΔC22) in the neural tube. Similar to wild type Hhip, HhipΔC22 inhibited ventral Hb9 expression when the electroporated cells were located dorsal to the Hb9 domain, demonstrating that both act multiple cell diameters away from the site of synthesis (Fig. 4c, d) . To assess the functionality of an obligatory membrane associated form of Hhip, we fused the transmembrane domain and intracellular tail of CD4 to the C-terminal end of HhipΔC22, Hhip:CD4. Robust expression of Hhip:CD4 next to the floor plate and source of Shh repressed Hb9 and deformed the neural tube like wild type Hhip (Fig. 5a, 1a) . Hhip:CD4 induction of Pax7 was completely cell autonomous (Fig. 5b) . In addition coexpressing Hhip:CD4 and SMOM2 only resulted in minor non-cell autonomous inhibition of the Shh response (Fig. 5c, d ). Furthermore, Hhip:CD4 was still susceptible to Shh/Smo mediated degradation (Fig. 5m) . These results further indicate that Hhip released from cells mediate part of the non-cell autonomous inhibition.
Discussion
The data shown provide a mechanism by which Hhip is able to act despite being near the Shh source, where Shh can activate the response by enhancing degradation of Hhip, while Hhip retains its non-cell autonomous effects on the Shh response. This explains an inconsistency in the prevailing model in which both Ptch1 and Hhip act as a cell autonomous Shh barrier. The Shh gradient should experience a steep decline in ligand concentrations at the sites of Ptch1/2 and Hhip expression in the neural tube, but such a steep decline of the Shh gradient is not observed. Our data now suggest a graded model where Hhip binds Shh, both at the cell surface and upon Hhip release from cells, to inhibit the Shh response non-cell autonomously.
Consistent with earlier findings, we find that Hhip inhibits the Shh response in neighboring cells. However, rather than just acting to cell autonomously sequester Shh to lower the amount of Shh available to neighboring cells, we find that Hhip is also released from the sites of synthesis to inhibit the Shh response at a distance. In particular our finding that Hhip can inhibit the Shh response in cells that are located between the Shh source and the sites of Hhip synthesis strongly indicates that Hhip is able to act at a distance. Our observation that SmoM2 rescues cells from the consequences of ectopically expressed Hhip from its inhibitory effects raised the question of why the normal sites of Hhip expression have an apparently unimpaired response to Shh. We showed that Shh, Smo, or SmoM2 causes a significant loss of cell-associated Hhip, which would counteract the cell autonomous inhibitory activity of Hhip. These results provide a new mechanism by which Hhip is able to act despite being near the Shh source where Shh can activate the response, while Hhip retains its non cell autonomous effects on the Shh response.
Besides its signaling functions, Ptch1 plays an important role as negative regulator in shaping the Shh gradient in the neural tube. Hh signaling induces the expression of Ptch1, which leads to more sequestration of Hh ligands, resulting in the creation of a barrier to further movement in the gradient 24 . It was proposed that Hhip functions in a comparable manner 6 One important consideration when interpreting our results and comparing them to previsouly published data, is the possibility of overexpression artefacts. We were unable to detect endogenous Hhip in the tissues studied, and as a consequence, we resorted to introducing Hhip by transfection or electroporation. This allowed us to perform the biochemical and in vivo analyses shown, but could possibly drive Hhip protein to levels that result in perturbed localization of Hhip. However, the ability of specific mutations (ΔARG) to counteract the effects of Smo on Hhip argues against such artefacts. An important consequence of this potential discrepancy between our system and the function and regulation of endogenous Hhip is the interpretation of the causal relationship between the translational induction of Hhip by Smo activation which is well known, versus the direct action of Smo on Hhip leading to its degradation that we observe.
The CRD in the extracellular domain of Smo has has been shown to be important in Smo dimerization with implications for Smo activation 27 . Additionally, SmoΔCRD has been shown to only mediate low to medium, but not high, levels of pathway activation despite being localized to cilia 19 . The level of Shh pathway activity mediated by Smo determines the fate of Hhip proteins, where high Shh activity decreases Hhip levels most. This is most likely the reason why the Shh response is not impaired where Shh is highly active and where Hhip is most highly expressed. This would also allow Hhip to reduce Shh ligands, as well as alter the localization of Smo which may decrease the magnitude and duration of the response in various ways.
In addition to being targeted by different inhibitory proteins, the stability of Shh ligands also affects how the gradient is maintained. For example, when Ptch1 and Shh bind, the complex is internalized and degraded by the cell, thus rapidly decreasing Shh levels 28 . In contrast, Hhip and Shh complexes appear to be more stable and stay at the cell surface much longer than Ptch1-Shh complexes 6 . With the addition of Hhip being secreted and able to bind Shh, this adds a new dimension to Hhip's role in Shh gradient formation.
Can Hhip function in a similar manner to other CRD-containing proteins that bind to morphogens to regulate either their activity or range? Examples of these proteins include such molecules as Chordin and soluble Frizzled-related proteins (SFRPs) that bind BMPs and WNTs/FRDs respectively. These proteins were both initially thought to inhibit pathway activation, however, data now point to a more complex function for these proteins. For example, SFRP and WNT complexes have been shown to increase long range WNT signaling 29 . In addition, Chordin binds to BMPs, preventing them from binding their receptors, thus inhibiting activation 30 . However, as Chordin and BMP complexes diffuse in a field, Chordin is cleaved by Tolloid, where this cleavage releases BMP and is allowed to activate the pathway 31 . With all these similarities between Hhip and SFRP and Chordin, it would be interesting to see if Hhip also plays a role in the long range transport of Shh ligands. Future studies will be needed to address this possibility.
Methods
Plasmids pcDNA3-mHhip was a gift from Dr. P.T. Chuang (UCSF). An N-terminal HA-tag was inserted after the Hhip signal sequence following amino acid 23. Using Quikchange mutagenesis (Agilent Technologies), deletions were created by targeting the following amino acids: 35-54 (HhipΔAR); 373-390 (HhipΔL2); 607-634 (HhipΔEGF); and 669-700 (HhipΔC22). The transmembrane and intracellular domain of CD4 was fused to the cterminal of HhipΔC22 to make Hhip:CD4. Hhip mutants were also subcloned into pMES-IRES-eGFP or pMES-IRES-tdTomato plasmids for in ovo electroporation.
In ovo electroporation
Chick embryo electroporation was performed as described 20 . Fertilized White Leghorn chicken eggs (Charles River Laboratories) were incubated at 38°C until embryos reached Hamburger and Hamilton (HH) stage 10. Eggs were windowed, and plasmid DNA resuspended at 2-5 μg/μl in PBS was injected into the neural tube of the embryo. Embryos were electroporated between 4 mm gap electrodes at 25 V, 5 × 25 ms pulses with an ECM-820 electroporator (BTX). After electroporation, embryos were incubated until they reached stage 18-20 HH, fixed, incubated in 30% sucrose/PBS overnight, mounted and frozen in OCT compound, and cryosectioned at 12-18 μm. Sections were washed 3x with PBS/0.01% TritonX-100 and blocked for 30 minutes with PBS/0.01% Triton X-100 in 5% donkey serum. Sections were immunostained with mouse anti-Pax7 (1:25), mouse anti-Hb9 (1:100) (both from the Developmental Studies Hybridoma Bank, Iowa City, IA), and rabbit anti-GFP (1:1000) (Invitrogen) for 2 hours at room temperature or overnight at 4°C. After washing with PBS/0.01% TritonX-100, the appropriate secondary antibodies added and were incubated for 1 hour. Images were obtained using routine fluorescence microscopy techniques on a Microphot-SA epifluorescence microscope (Nikon) or an Axio Observer Z1 (Zeiss, Jena, Germany) fluorescence microscope.
Immunofluorescent staining
Madin-Darby canine kidney (MDCK) cells (ATCC CCL-34) were transfected with either pcDNA3.1-HA-Hhip, including a plasmid expressing GFP, or pRK5-Shh using Lipofectamine LTX and Plus Reagent (Invitrogen). After 24 hours, cells were detached, mixed together, and cultured overnight. Cells were fixed using 4% formaldehyde in PBS, blocked with PBS/0.01% Triton X-100 with 5% goat serum and subsequently incubated with the following primary antibodies: rat anti-HA (1:500) (3F10, Roche Applied Science) and rabbit anti-Shh (1:100) (H160, SCBT) overnight at 4°C. Slides were washed and then incubated with the following secondary antibodies: Alexa-488 anti-Rat IgG and Alexa-568 anti-rabbit (1:1,000) (Invitrogen). Cell images were acquired on an Axio Observer Z1 microscope.
Co-immunoprecipitation and co-expression
HEK 293T cells (ATCC CRL-3216) were transfected with DNA using Lipofectamine 2000 (Invitrogen). For co-immunoprecipitation, cells were detached with PBS/0.5 mM EDTA 24 hours after transfection, and co-cultured overnight in Optimem (Invitrogen). Supernatants were collected and cleared by centrifugation. Cells were lysed (25 mM Hepes, 150 mM NaCl, 1% IGEPAL CA-630, 1 mM Na3VO4, and protease cocktail inhibitor) and cleared. Lysates and supernatants were immunoprecipitated with Hhip antibody (1.6 μg/sample) (M-17, SCBT) or anti-HA (4 μl/sample) (Sigma). For co-expression experiments, HEK 293T cells were co-transfected as for the coculture experiments.. For the inhibition of degradation, cells were treated with chloroquine (Sigma), folimycin A (Calbiochem), or MG132 (Calbiochem). After 48 hours, cells were directly lysed in 1x NuPAGE LDS sample buffer (Invitrogen). Lysates were run on NuPAGE precast gels (Invitrogen) and transferred to membrane using the iBlot gel transfer system. Membranes were blocked in 5% milk in TBS/0.1% Tween-20 for 1h and incubated in the following primary antibodies overnight at 4°C:: rat anti-HA (1:10,000); rabbit anti-Shh (1:1000) antibody and mouse-anti-myc (1:10,000) (9B11, Cell Signaling Technology); and mouse anti-gD (1:10,000) (clone ID3). The next day, membranes were washed and incubated in the appropriate secondary antibodies (1:10,000) for 1-3h and ECL was imaged using film. Uncropped images of HA and Hhip blots are shown in supplementary Fig. 1 . Fisher's exact test shows that the effects of Hhip p<0.0001 (n=10); HhipΔAR p<0.0001 (n=11), and HhipΔEGF p=0.0152 (n=6) are significant. HhipΔLp2 has no effect; p=1 (n=10). Scale bar: 50 μm (q). 
